[go: up one dir, main page]

CY1120803T1 - ANTIGONE BINDING PROTEINS SPECIFIC FOR THE STRUCTURE OF STARCH - Google Patents

ANTIGONE BINDING PROTEINS SPECIFIC FOR THE STRUCTURE OF STARCH

Info

Publication number
CY1120803T1
CY1120803T1 CY181101126T CY181101126T CY1120803T1 CY 1120803 T1 CY1120803 T1 CY 1120803T1 CY 181101126 T CY181101126 T CY 181101126T CY 181101126 T CY181101126 T CY 181101126T CY 1120803 T1 CY1120803 T1 CY 1120803T1
Authority
CY
Cyprus
Prior art keywords
binding proteins
antigone
starch
antigen
proteins specific
Prior art date
Application number
CY181101126T
Other languages
Greek (el)
Inventor
Tejinder Kaur Bhinder
Susannah Karen Ford
Volker Germaschewski
Alan Peter Lewis
Mark Brian Pepys
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43881068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120803(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CY1120803T1 publication Critical patent/CY1120803T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε πρωτεΐνες δέσμευσης με αντιγόνο, όπως αντισώματα, που δεσμεύονται με το συστατικό Ρ αμυλοειδούς ορού (SAP), πολυνουκλεοτίδια που κωδικοποιούν τέτοιες πρωτεΐνες σύνδεσης με αντιγόνο, σε φαρμακευτικές συνθέσεις που περιέχουν τις εν λόγω πρωτεΐνες δέσμευσης με αντιγόνο και σε μεθόδους παραγωγής. Η παρούσα εφεύρεση αφορά επίσης τη χρήση τέτοιων πρωτεϊνών δέσμευσης με αντιγόνο στη θεραπεία ή προφύλαξη νόσων συνδεόμενων με την εναπόθεση αμυλοειδούς όπου περιλαμβάνονται η συστημική αμυλοείδωση, τοπική αμυλοείδωση, νόσος Alzheimer, και διαβήτης τύπου 2.The present invention relates to antigen-binding proteins, such as antibodies, bound to component P amyloid serum (SAP), polynucleotides encoding such antigen-binding proteins, to pharmaceutical compositions containing said anti-binding proteins and . The present invention also relates to the use of such antigen binding proteins in the treatment or prophylaxis of amyloid deposition-related diseases including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

CY181101126T 2010-03-03 2018-10-31 ANTIGONE BINDING PROTEINS SPECIFIC FOR THE STRUCTURE OF STARCH CY1120803T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30995710P 2010-03-03 2010-03-03
EP11705617.6A EP2542261B1 (en) 2010-03-03 2011-03-01 Antigen binding proteins specific for serum amyloid p component
PCT/EP2011/053038 WO2011107480A1 (en) 2010-03-03 2011-03-01 Antigen binding proteins specific for serum amyloid p component

Publications (1)

Publication Number Publication Date
CY1120803T1 true CY1120803T1 (en) 2019-12-11

Family

ID=43881068

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100950T CY1118046T1 (en) 2010-03-03 2016-09-23 BINDING PROTEINS WITH ANTIGEN SPECIFIC TO THE AMYLOID COMPONENT
CY181101126T CY1120803T1 (en) 2010-03-03 2018-10-31 ANTIGONE BINDING PROTEINS SPECIFIC FOR THE STRUCTURE OF STARCH

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100950T CY1118046T1 (en) 2010-03-03 2016-09-23 BINDING PROTEINS WITH ANTIGEN SPECIFIC TO THE AMYLOID COMPONENT

Country Status (40)

Country Link
EP (2) EP3025729B1 (en)
JP (2) JP5922592B2 (en)
KR (1) KR101817265B1 (en)
CN (1) CN102858371B (en)
AR (1) AR080432A1 (en)
AU (1) AU2011223048C1 (en)
BR (1) BR112012021926A2 (en)
CA (1) CA2789557A1 (en)
CL (1) CL2012002418A1 (en)
CO (1) CO6602134A2 (en)
CR (1) CR20120491A (en)
CY (2) CY1118046T1 (en)
DK (2) DK2542261T3 (en)
DO (1) DOP2012000232A (en)
EA (1) EA026375B1 (en)
ES (2) ES2699078T3 (en)
HK (2) HK1173959A1 (en)
HR (2) HRP20161096T1 (en)
HU (1) HUE028960T2 (en)
IL (2) IL221418A (en)
JO (1) JO3188B1 (en)
LT (2) LT2542261T (en)
MA (1) MA34135B1 (en)
ME (1) ME02491B (en)
MX (1) MX340350B (en)
MY (1) MY159255A (en)
NZ (1) NZ601763A (en)
PE (1) PE20130040A1 (en)
PH (1) PH12012501743A1 (en)
PL (2) PL2542261T3 (en)
PT (2) PT2542261T (en)
RS (2) RS55133B1 (en)
SG (2) SG10201500382SA (en)
SI (2) SI3025729T1 (en)
SM (2) SMT201800633T1 (en)
TW (1) TWI558409B (en)
UA (1) UA108227C2 (en)
UY (1) UY33258A (en)
WO (1) WO2011107480A1 (en)
ZA (1) ZA201206529B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012012887A2 (en) * 2009-12-02 2017-05-02 Imaginab Inc nucleotide sequence-coded minibody and cys-diabody (cysdb), their use and methods for diagnosing and treating cancer associated with psma expression in a subject.
EA031025B1 (en) * 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Anti-ntb-a antibodies and related compositions and methods
CN103239713A (en) * 2013-05-28 2013-08-14 东南大学 Method for building diabetic nephropathy microinflammation mice model
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
US9737505B2 (en) * 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
JP7026613B2 (en) 2015-08-07 2022-02-28 イマジナブ・インコーポレーテッド Antigen binding construct for target molecule
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2019185502A1 (en) 2018-03-26 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Antibodies comprising methionine sulfoxide at the ch2-ch3 interface
CN116925216B (en) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 Anti-serum amyloid A antibody, reagent for detecting serum amyloid A and kit

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. CHANGED ANTIBODIES.
ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69229477T2 (en) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methods for the production of humanized antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
US6193969B1 (en) 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
JP2001512308A (en) 1997-02-07 2001-08-21 メルク エンド カンパニー インコーポレーテッド Synthetic HIV GAG gene
DK0915088T3 (en) * 1997-10-31 2003-01-27 Hoffmann La Roche D-proline derivatives
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
KR20100018071A (en) 2001-08-03 2010-02-16 글리카트 바이오테크놀로지 아게 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6903129B2 (en) 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
JP4580340B2 (en) 2002-09-27 2010-11-10 ゼンコー・インコーポレイテッド Optimized Fc variants and methods for their generation
ES2318195T3 (en) 2002-12-23 2009-05-01 William Marsh Rice University METHODS AND COMPOSITIONS TO POTENTIATE THE FORMATION OF FIBROCITS.
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
CA2525302A1 (en) 2003-05-12 2004-11-18 David Bundle Multivalent inhibitors of serum amyloid p component
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
WO2009155962A1 (en) * 2008-06-27 2009-12-30 Pentraxin Therapeutics Limited Use

Also Published As

Publication number Publication date
CN102858371A (en) 2013-01-02
PE20130040A1 (en) 2013-02-09
JP2016154535A (en) 2016-09-01
SMT201600337B (en) 2016-11-10
MX2012010129A (en) 2012-09-12
MX340350B (en) 2016-07-06
NZ601763A (en) 2014-08-29
SI2542261T1 (en) 2016-11-30
ES2699078T3 (en) 2019-02-07
TW201143789A (en) 2011-12-16
PL3025729T3 (en) 2019-02-28
TWI558409B (en) 2016-11-21
WO2011107480A1 (en) 2011-09-09
EP3025729B1 (en) 2018-09-12
RS57708B1 (en) 2018-12-31
PL2542261T3 (en) 2016-12-30
JP6236478B2 (en) 2017-11-22
PT3025729T (en) 2018-11-30
SI3025729T1 (en) 2018-11-30
MA34135B1 (en) 2013-04-03
PH12012501743A1 (en) 2012-11-12
HK1173959A1 (en) 2013-05-31
EA026375B1 (en) 2017-04-28
KR20130027483A (en) 2013-03-15
HRP20181666T1 (en) 2018-12-14
LT3025729T (en) 2018-12-10
HUE028960T2 (en) 2017-01-30
IL221418A0 (en) 2012-10-31
KR101817265B1 (en) 2018-01-10
CO6602134A2 (en) 2013-01-18
EP2542261B1 (en) 2016-07-06
ES2593454T3 (en) 2016-12-09
UA108227C2 (en) 2015-04-10
IL251031A0 (en) 2017-04-30
AU2011223048C1 (en) 2018-06-21
JP2013521252A (en) 2013-06-10
CN102858371B (en) 2017-03-01
EP2542261A1 (en) 2013-01-09
BR112012021926A2 (en) 2020-08-25
CA2789557A1 (en) 2011-09-09
PT2542261T (en) 2016-09-27
JO3188B1 (en) 2018-03-08
JP5922592B2 (en) 2016-05-24
CL2012002418A1 (en) 2013-03-08
IL251031A (en) 2017-11-30
SG10201500382SA (en) 2015-03-30
HRP20161096T1 (en) 2016-11-04
ME02491B (en) 2017-02-20
AU2011223048B2 (en) 2013-12-19
ZA201206529B (en) 2018-12-19
AU2011223048A1 (en) 2012-10-04
UY33258A (en) 2011-09-30
LT2542261T (en) 2016-09-26
MY159255A (en) 2016-12-30
SG183316A1 (en) 2012-09-27
DK2542261T3 (en) 2016-09-19
SMT201800633T1 (en) 2019-01-11
EA201290671A1 (en) 2013-05-30
DOP2012000232A (en) 2013-01-15
AR080432A1 (en) 2012-04-11
CY1118046T1 (en) 2017-05-17
CR20120491A (en) 2013-02-20
RS55133B1 (en) 2016-12-30
HK1223292A1 (en) 2017-07-28
EP3025729A1 (en) 2016-06-01
DK3025729T3 (en) 2018-11-26
IL221418A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
CY1120803T1 (en) ANTIGONE BINDING PROTEINS SPECIFIC FOR THE STRUCTURE OF STARCH
CY1121392T1 (en) COMBINATION MOLECULES AGAINST ALPHA-SYNUCLEIN
CY1122458T1 (en) ANTI-N3PGLU AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
CU20170169A7 (en) FACTOR ANTIBODIES XI
ECSP12012272A (en) PROTEINS THAT JOIN TNF-?
EA201891165A1 (en) MOLECULES BINDING PD1 AND / OR LAG3
UA116772C2 (en) SELECTED MONOCLONAL ANTIBODY OR ITS IMMUNOLOGICAL-ACTIVE Fragment Binding to CD47
CR20130624A (en) PROTEINS OF UNION TO ANTIGEN
CY1117563T1 (en) HER3 PARTS AND USE OF THESE
UA118332C2 (en) Cs27l antigen binding proteins
EA201291067A1 (en) HUMANIZED ANTIGENSORATING PROTEINS FOR MYOSTATIN
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
UA117364C2 (en) Amatoxin derivatives
CO6710903A2 (en) An antibody that specifically recognizes and binds with a phospho-epitope in the mammalian tau protein or in one of its fragments and a composition comprising the same
EA201290849A1 (en) OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR (TFPI)
EA201290570A1 (en) CONSTRUCTIONS CONNECTING WITH RON AND METHODS OF THEIR USE
UA116194C2 (en) ANTIBODY THAT SPECIFICALLY Binds to HUMAN ALPHA SYNUCLEIN
MX2011011754A (en) COMPOSITIONS AND METHODS FOR ANTIBODIES THAT GO TO THE COMPLEMENT PROTEIN C3B.
MA34004B1 (en) Protein link cd127
CY1115349T1 (en) CXCR4 CLEANED ANTIBODIES FOR CANCER TREATMENT
CY1119890T1 (en) TREATMENT TREATMENT OF TREATMENT USING SPECIAL ANTI-ANTI-L1
EA201301107A1 (en) MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR (TFPI)
EA201990895A1 (en) ANTIBODIES TO O1 AND OPTIONS OF THEIR APPLICATION
BR112015012708A2 (en) antibodies to bmp-6
EA202191666A1 (en) ANTIBODIES TO IL-27 AND THEIR USE